Ashleigh S Davey
Overview
Explore the profile of Ashleigh S Davey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elazar A, Chandler N, Davey A, Weinstein J, Nguyen J, Trenker R, et al.
Elife
. 2022 May;
11.
PMID: 35506657
De novo-designed receptor transmembrane domains (TMDs) present opportunities for precise control of cellular receptor functions. We developed a de novo design strategy for generating programmed membrane proteins (proMPs): single-pass α-helical...
2.
3.
Davey A, Call M, Call M
Cancers (Basel)
. 2020 Dec;
13(1).
PMID: 33375550
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of B cell malignancies, improving patient survival and long-term remission. Nonetheless, over 50% of patients experience severe treatment-related toxicities including...
4.
Van Audenaerde J, Marcq E, Von Scheidt B, Davey A, Oliver A, De Waele J, et al.
Clin Transl Immunology
. 2020 Aug;
9(8):e1165.
PMID: 32821382
Objectives: With the poorest 5-year survival of all cancers, improving treatment for pancreatic cancer is one of the biggest challenges in cancer research. We sought to explore the potential of...
5.
Chan J, Von Scheidt B, Zeng B, Oliver A, Davey A, Ali A, et al.
Clin Transl Immunology
. 2020 Jul;
9(7):e1157.
PMID: 32704371
Objectives: Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells is a form of cancer immunotherapy that has achieved remarkable efficacy in patients with some haematological cancers. However, challenges remain...
6.
Oliver A, Davey A, Keam S, Mardiana S, Chan J, Von Scheidt B, et al.
Clin Transl Immunology
. 2019 Nov;
8(11):e1094.
PMID: 31768254
Objectives: Investigation of variable response rates to cancer immunotherapies has exposed the immunosuppressive tumor microenvironment (TME) as a limiting factor of therapeutic efficacy. A determinant of TME composition is the...